Embolic Agents

Embolic Agents Market Outlook

The global embolic agents market was valued at approximately USD 4.7 billion in 2023 and is projected to reach around USD 8.5 billion by 2035, with a compound annual growth rate (CAGR) of 7.4% during the forecast period. This significant growth is primarily attributed to increasing prevalence of vascular diseases, advancements in minimally invasive surgical techniques, and rising geriatric population that is more susceptible to embolic events. Further driving this market is the growing number of interventional procedures, such as embolization, facilitated by enhanced healthcare infrastructure and technological innovations in medical devices. Additionally, the increasing demand for targeted cancer therapies through embolic agents in oncology will continue to spur market growth, as well as the overall trend towards outpatient care and specialty clinics for surgical interventions.

Growth Factor of the Market

The embolic agents market is experiencing robust growth due to several factors converging to enhance its expansion trajectory. One of the primary growth drivers is the increasing incidence of chronic diseases, particularly cardiovascular conditions and cancer, which necessitate the use of embolization techniques. Furthermore, advancements in medical imaging and catheterization technologies have led to improved procedural accuracy and patient outcomes, making embolic procedures more appealing to healthcare providers and patients alike. The shift towards minimally invasive methodologies is also contributing significantly, as these procedures generally result in shorter recovery times and reduced hospitalization costs. Moreover, rising investments in healthcare R&D are fostering innovation in embolic materials, such as drug-eluting microspheres and advanced coil designs, enhancing treatment efficacy and safety profiles. Finally, growing awareness regarding the advantages of embolization is promoting its adoption in various therapeutic applications, further fueling market growth.

Key Highlights of the Market

• The market is projected to grow at a CAGR of 7.4% from 2023 to 2035.
• North America holds the largest market share due to high healthcare expenditure and advanced healthcare infrastructure.
• Liquid embolic agents are witnessing significant growth owing to their versatility and effectiveness in various applications.
• Oncology applications are expected to dominate the market due to the increasing incidence of liver cancer and other malignancies.
• Technological innovations in embolic agents are enhancing procedural outcomes and expanding the scope of applications.

By Product Type

Coil Embolic Agents:

Coil embolic agents are among the most commonly utilized materials for vascular occlusion procedures. They consist of soft, flexible coils that are designed to induce thrombosis in targeted blood vessels. These devices are highly effective for embolizing aneurysms and vascular malformations due to their ability to conform to the vessel geometry. The growing preference for coil embolic agents can be attributed to their simplicity of use and the high success rate associated with their application in various vascular procedures. The coils can be made of various materials, including platinum, stainless steel, or other polymers, which cater to different clinical needs. Furthermore, advancements in coil technology, such as the introduction of bioactive coils, are enhancing their efficacy, thus driving their demand in the market.

Liquid Embolic Agents:

Liquid embolic agents are gaining traction in the embolic agents market due to their ability to fill complex vascular structures and provide more complete occlusion. These agents, which include materials such as Onyx and Ethylene Vinyl Alcohol (EVA), can be injected in a liquid form and solidify upon contact with blood, thereby blocking blood flow effectively. Liquid embolics are particularly suitable for use in neurovascular procedures and in treating lesions that are not amenable to traditional solid agents like coils. Additionally, their adaptability to various delivery systems has made them a preferred choice among interventional radiologists. As procedural safety and efficacy continue to improve with innovations in liquid formulations, the demand for liquid embolic agents is expected to rise steadily.

Particulate Embolic Agents:

Particulate embolic agents comprise small particles that are designed to occlude blood vessels in a controlled manner. These agents can be made from various materials, including polyvinyl alcohol and gelatin, and are used primarily in the treatment of hypervascular tumors and arteriovenous malformations. The versatility of particulate agents allows them to be used in a variety of applications, including urology and oncology, thus expanding their market reach. Their ability to provide selective embolization while minimizing damage to surrounding tissues has made them a preferred option in many interventional procedures. The increasing use of particulate agents in combination with imaging techniques, further enhances their safety and effectiveness, driving their growth in the embolic agents market.

Drug-Eluting Microspheres:

Drug-eluting microspheres are a novel class of embolic agents designed to deliver therapeutic agents directly to the target site while simultaneously occluding blood flow. They are particularly effective in the treatment of tumors and other hypervascular lesions, offering a dual benefit of local drug delivery and vessel occlusion. The increasing incidence of cancer and the need for targeted therapies have led to a surge in demand for drug-eluting microspheres. Their customizable nature allows for precise control over drug release rates, making them highly effective in achieving desired therapeutic outcomes. As the field of interventional oncology continues to evolve, the role of drug-eluting microspheres is expected to expand, significantly impacting their market share in the coming years.

Gelatin Sponge:

Gelatin sponge embolic agents are biodegradable materials that are used for temporary occlusion in various surgical procedures. They are particularly valued for their ease of use and ability to conform to the vascular anatomy. Gelatin sponges can be used in a wide array of applications, including in peripheral vascular disease and for controlling bleeding during surgical interventions. The inherent biocompatibility and biodegradability of gelatin sponges make them a favorable choice among healthcare professionals, particularly in emergency and trauma settings. Their temporary nature allows for subsequent revascularization, making them a safe option for many procedures. As advancements in gelatin formulations continue to enhance their performance, their acceptance and usage within the market are likely to increase.

By Application

Peripheral Vascular Disease:

Peripheral vascular disease (PVD) is a significant application area for embolic agents, as it involves the narrowing or blockage of blood vessels outside the heart and brain. Embolic agents play a critical role in the management of PVD by occluding targeted vessels to improve blood flow and alleviate symptoms. The increasing prevalence of PVD, driven by factors such as diabetes, obesity, and smoking, is propelling the demand for effective embolization solutions within this segment. Additionally, advancements in imaging techniques that facilitate precise embolization are further enhancing the efficacy of these treatments and driving their adoption in clinical practice.

Neurology:

In the field of neurology, embolic agents are primarily utilized for the treatment of conditions such as arteriovenous malformations (AVMs) and cerebral aneurysms. The effectiveness of embolization in these intricate vascular structures has made embolic agents a cornerstone in neurosurgical interventions. Given the rising incidence of neurological disorders and the increasing number of minimally invasive procedures, the demand for embolic agents in the neurology segment is experiencing significant growth. Additionally, innovations in embolic materials that improve delivery systems and enhance procedural outcomes are likely to facilitate further expansion of this market segment.

Oncology:

The oncology application segment is witnessing exponential growth due to the increasing global incidence of cancer. Embolic agents are used in transarterial chemoembolization (TACE) to treat liver tumors and in other targeted therapies for hypervascular tumors. The ability of embolic agents to both occlude blood vessels and deliver therapeutic agents directly to the tumor site enhances treatment efficacy and minimizes systemic side effects. As the focus shifts towards personalized cancer therapies, the role of embolic agents in oncological procedures is expected to expand significantly, driving market growth in this segment.

Urology:

In urology, embolic agents are used primarily to manage conditions such as renal tumors and hemorrhagic complications. Embolization in the renal arteries can effectively control bleeding and improve the outcomes of surgical interventions. The increasing prevalence of renal diseases and the growing number of non-invasive approaches are propelling the demand for embolic agents in urology. Moreover, technological advancements in imaging and delivery systems are enhancing procedural success rates, making embolization a preferred option among urologists.

Others:

The 'Others' category includes various applications of embolic agents that do not fall under the primary categories mentioned above. This encompasses applications in areas such as gynecology, gastroenterology, and pain management. The increasing recognition of the potential benefits of embolization in these fields is driving the growth of this segment. Additionally, the development of specialized embolic agents tailored for specific clinical scenarios is likely to expand the scope and applications of embolic therapies in diverse medical specialties.

By Distribution Channel

Hospitals:

Hospitals are the primary distribution channel for embolic agents, accounting for a substantial share of the market. The presence of specialized interventional radiology departments and surgical teams within hospitals facilitates the administration of embolic agents for various procedures. The growing number of interventional procedures performed in hospitals, driven by increasing patient volume and advancements in surgical techniques, is propelling the demand for embolic agents in this channel. Additionally, hospitals' ability to invest in advanced medical technologies amplifies their capability to adopt and utilize sophisticated embolic devices effectively.

Specialty Clinics:

Specialty clinics are emerging as a significant distribution channel for embolic agents due to their focus on specific therapeutic areas, such as oncology or vascular surgery. These clinics often employ an advanced treatment approach and offer streamlined patient care, making them ideal settings for the application of embolic therapies. The increasing trend of outpatient procedures and the rise of interventional specialists in these clinics are contributing to the growing demand for embolic agents. Furthermore, the focus on patient-centric care within specialty clinics aligns well with the evolving landscape of vascular interventions.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) have become a favorable distribution channel for embolic agents as they cater to the rising demand for outpatient care. Procedures such as embolization are increasingly being performed in ASCs due to their efficiency, cost-effectiveness, and patient convenience. The shift towards outpatient care, coupled with the growing acceptance of minimally invasive techniques, is driving the adoption of embolic agents in these settings. ASCs also benefit from lower overhead costs, making them an attractive option for both providers and patients.

Catheterization Laboratories:

Catheterization laboratories, commonly found within hospitals and specialized clinics, are crucial environments for the application of embolic agents in interventional radiology and cardiology. These labs are equipped with advanced imaging and surgical technologies to perform vascular interventions with high precision. The growing number of catheter-based procedures and the rising prevalence of vascular diseases are propelling the demand for embolic agents within catheterization laboratories. Furthermore, the integration of cutting-edge imaging techniques within these labs enhances procedural accuracy, driving the use of embolic materials.

Others:

The 'Others' category encompasses various other distribution channels for embolic agents, such as online platforms and direct sales to healthcare providers. The advent of telemedicine and digital healthcare solutions is gradually creating alternative avenues for the distribution of medical products, including embolic agents. The increasing acceptance of digital platforms for ordering medical supplies is likely to facilitate the growth of this distribution segment. Additionally, direct sales strategies adopted by manufacturers to engage with healthcare providers can enhance accessibility to embolic agents across various healthcare settings.

By Ingredient Type

Polyvinyl Alcohol:

Polyvinyl alcohol (PVA) is a widely used ingredient in the formulation of particulate embolic agents. Its biocompatibility and ability to create a reliable occlusion make it a preferred choice in various interventional procedures. PVA particles are available in different sizes, allowing for selective occlusion of blood vessels based on the clinical requirements. The growing prevalence of applications in oncology, urology, and other fields is bolstering the demand for PVA-based embolic agents. Additionally, ongoing research into enhancing PVA formulations is likely to further expand its role in embolization therapies.

Microspheres:

Microspheres have gained popularity in the embolic agents market due to their ability to provide controlled and targeted embolization. These small spherical particles can be loaded with therapeutic agents, such as chemotherapy drugs, enabling localized treatment while occluding blood flow. The increasing demand for drug delivery systems in oncology and other applications is propelling the growth of microsphere-based embolic agents. Furthermore, advancements in microsphere technology are enhancing their efficacy and safety, driving their adoption in clinical practice.

Gelatin:

Gelatin is a biodegradable ingredient commonly used in the formulation of embolic agents, particularly gelatin sponge embolics. Its natural properties allow for temporary occlusion in various surgical procedures, making it a valuable tool in managing bleeding and vascular conditions. Due to its biocompatibility and ease of use, gelatin-based embolics are frequently utilized in emergency settings. The increasing awareness regarding the benefits of biodegradable materials in minimally invasive procedures is driving the demand for gelatin as an ingredient in embolic agents.

Onyx:

Onyx is a liquid embolic agent that has gained recognition for its effectiveness in treating complex vascular malformations and tumors. Its unique formulation allows it to provide prolonged occlusion while facilitating the targeted delivery of therapeutic agents. Onyx is particularly favored in neurovascular interventions due to its ability to fill intricate vascular spaces. The growing incidence of neurovascular diseases and the demand for effective treatment modalities are driving the adoption of Onyx as a key ingredient in embolic therapies. As innovations in liquid embolics continue to evolve, Onyx is positioned for further growth in the market.

Others:

The 'Others' category includes various additional ingredient types used in the formulation of embolic agents, such as polyethylene and other proprietary materials. These ingredients may offer unique properties that cater to specific clinical needs or procedural requirements. The continued research and development efforts aimed at creating novel embolic substances are likely to expand this segment further. The diversification in ingredient types is essential for addressing diverse clinical scenarios, thereby enhancing the overall effectiveness of embolic therapies.

By Region

The North American embolic agents market is the largest globally, accounting for approximately 45% of the total market share in 2023. This dominance can be attributed to high healthcare expenditure, advanced healthcare infrastructure, and increased adoption of minimally invasive surgical techniques in interventional procedures. The United States, in particular, is at the forefront of innovation in medical devices, including embolic agents, which is significantly contributing to market growth. The CAGR for this region is estimated at around 6.9%, reflecting robust demand for embolization procedures and the continuous development of novel embolic materials.

Europe comes in second, holding approximately 30% of the global embolic agents market share. The region benefits from a well-established healthcare system, increasing awareness regarding embolization procedures, and a growing geriatric population necessitating vascular interventions. Countries such as Germany, France, and the UK are leading contributors in the European embolic agents market, with a projected CAGR of 7.2% during the forecast period. The Asia Pacific region is also expected to exhibit significant growth, driven by increasing healthcare spending, rapid urbanization, and rising prevalence of chronic diseases. As emerging economies like India and China continue to invest in healthcare infrastructure, the regional market is projected to expand substantially over the coming years.

Opportunities

The embolic agents market is poised for significant growth, driven by a plethora of opportunities that are emerging as the healthcare landscape continues to evolve. One of the most promising opportunities lies in the increasing adoption of minimally invasive surgical techniques. As healthcare providers increasingly shift towards outpatient care, the demand for effective and reliable embolization solutions is set to rise correspondingly. This shift not only enhances patient outcomes by reducing recovery times but also minimizes overall healthcare costs, making embolic agents an attractive option for both providers and patients. Moreover, ongoing advancements in imaging technologies that enhance procedural accuracy are likely to catalyze the growth of the embolic agents market, creating opportunities for new product development and innovation.

Additionally, the growing focus on personalized medicine presents a vast opportunity in the embolic agents market. The ability to customize embolic agents for specific clinical scenarios can significantly enhance treatment efficacy, leading to better patient outcomes. As healthcare systems increasingly recognize the importance of targeted therapies, the demand for specialized embolic formulations is expected to rise. Furthermore, the expansion of clinical applications of embolization beyond traditional settings into new areas, such as gynecology and pain management, will open up additional avenues for growth. Lastly, strategic collaborations between manufacturers and healthcare providers will facilitate the development and adoption of advanced embolic agents, further propelling market growth.

Threats

Despite the favorable outlook for the embolic agents market, several threats could hinder its growth potential. One of the primary concerns is the stringent regulatory framework governing the approval and commercialization of medical devices. The lengthy and challenging approval processes for new embolic products can delay their entry into the market, limiting innovation and product availability. Additionally, the high costs associated with research and development, coupled with the need for clinical trials, can act as a barrier for smaller companies aiming to introduce novel embolic agents. The competitive landscape is also intensifying, with numerous established players vying for market share, potentially leading to price wars and decreased profit margins.

Another significant threat stems from the potential for adverse events or complications associated with embolic procedures. These risks can deter healthcare providers from adopting new embolic technologies, particularly in high-stakes environments such as neurovascular or oncology interventions. Furthermore, the increasing trend towards non-invasive or alternative treatment methodologies could pose a threat to traditional embolic agents, as patients and providers alike may lean towards less invasive options. Addressing these threats through robust regulatory strategies and effective risk management will be crucial to ensuring sustained growth in the embolic agents market.

Competitor Outlook

• Medtronic plc
• Boston Scientific Corporation
• Terumo Corporation
• Johnson & Johnson
• Cook Medical
• AngioDynamics Inc.
• Penumbra Inc.
• Halyard Health, Inc.
• Embolx, Inc.
• BTG plc
• Merit Medical Systems, Inc.
• Cardinal Health, Inc.
• RenalGuard Solutions, Inc.
• Vascular Solutions, Inc.
• Guerbet Group

The competitive landscape of the embolic agents market is characterized by the presence of several key players striving to maintain their market positions through strategic mergers, acquisitions, and partnerships. The market is dominated by established companies such as Medtronic, Boston Scientific, and Terumo, which boast extensive product portfolios, robust research capabilities, and a global reach. These companies are continually investing in innovation and the development of advanced embolic materials, such as liquid embolics and drug-eluting microspheres, to address evolving clinical needs and enhance treatment outcomes. With their substantial financial resources and expertise, these leading firms are well-positioned to capitalize on the growing demand for embolization solutions.

Emerging companies, including Embolx and BTG, are also making significant strides in the embolic agents market by introducing cutting-edge technologies and specialized products. These firms often focus on niche applications and innovative approaches to embolization, catering to specific patient needs or enhancing procedural efficacy. The increasing collaboration between established companies and smaller innovators fosters an ecosystem conducive to the development of novel embolic agents, thereby driving competition and advancing overall market growth. As the market continues to evolve, the competitive landscape is expected to shift, with new entrants potentially disrupting traditional paradigms and introducing fresh perspectives on embolization therapies.

Furthermore, key players in the embolic agents market are focusing on strategies to enhance their product offerings and improve patient outcomes. For instance, companies like Johnson & Johnson and Cook Medical are investing in research and development to explore new embolic materials and delivery systems that can improve the precision and effectiveness of embolization procedures. The emphasis on technology integration, such as combining embolic agents with advanced imaging techniques, is likely to set apart leading firms in the market. As the competition intensifies, strategic alliances and partnerships will play a crucial role in expanding market reach and accelerating product development, ultimately shaping the future of the embolic agents market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 BTG plc
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Cook Medical
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Embolx, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Guerbet Group
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Medtronic plc
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Penumbra Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Johnson & Johnson
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 AngioDynamics Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Terumo Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Halyard Health, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Cardinal Health, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Vascular Solutions, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 RenalGuard Solutions, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Merit Medical Systems, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Boston Scientific Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Embolic Agents Market, By Application
    • 6.1.1 Peripheral Vascular Disease
    • 6.1.2 Neurology
    • 6.1.3 Oncology
    • 6.1.4 Urology
    • 6.1.5 Others
  • 6.2 Embolic Agents Market, By Product Type
    • 6.2.1 Coil Embolic Agents
    • 6.2.2 Liquid Embolic Agents
    • 6.2.3 Particulate Embolic Agents
    • 6.2.4 Drug-Eluting Microspheres
    • 6.2.5 Gelatin Sponge
  • 6.3 Embolic Agents Market, By Ingredient Type
    • 6.3.1 Polyvinyl Alcohol
    • 6.3.2 Microspheres
    • 6.3.3 Gelatin
    • 6.3.4 Onyx
    • 6.3.5 Others
  • 6.4 Embolic Agents Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Catheterization Laboratories
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Embolic Agents Market by Region
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Embolic Agents market is categorized based on

By Product Type

• Coil Embolic Agents
• Liquid Embolic Agents
• Particulate Embolic Agents
• Drug-Eluting Microspheres
• Gelatin Sponge

By Application

• Peripheral Vascular Disease
• Neurology
• Oncology
• Urology
• Others

By Distribution Channel

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Catheterization Laboratories
• Others

By Ingredient Type

• Polyvinyl Alcohol
• Microspheres
• Gelatin
• Onyx
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Medtronic plc
• Boston Scientific Corporation
• Terumo Corporation
• Johnson & Johnson
• Cook Medical
• AngioDynamics Inc.
• Penumbra Inc.
• Halyard Health, Inc.
• Embolx, Inc.
• BTG plc
• Merit Medical Systems, Inc.
• Cardinal Health, Inc.
• RenalGuard Solutions, Inc.
• Vascular Solutions, Inc.
• Guerbet Group